Results 211 to 220 of about 102,308 (347)

Atypical presentation of H1N1-induced thrombotic microangiopathy with CD46 gene mutation
. [PDF]

Clin Nephrol Case Stud
Pal A, Aydin-Ghormoz E, Mehta S, Hajianpour MJ, Gaine E, Zia MA, Tannous E, Lightle A, Hongalgi K.   +8 more
europepmc   +1 more source

Conformational changes in fibrinogen elicited by its interaction with platelet membrane glycoprotein GPIIb-IIIa.

, 1993
Tatiana P. Ugarova, Andrei Z. Budzynski, Sanford J. Shattil, Zaverio M. Ruggeri, Mark H. Ginsberg, Edward F. Plow   +5 more
openalex   +1 more source

Risk of Alzheimer's disease in Down syndrome: Insights gained by multi‐omics

Alzheimer's &Dementia, Volume 21, Issue 4, April 2025.
Abstract Individuals with Down syndrome (DS) are highly susceptible to Alzheimer's disease (AD). The integration of genomics, transcriptomics, epigenomics, proteomics, and metabolomics enables unprecedented understanding of DS‐AD, offering a detailed picture of this complex issue. The vast ‐omics data also present challenges that reflect the complexity
Hui‐Qi Qu, Yichuan Liu, John J. Connolly, Frank D. Mentch, Charlly Kao, Hakon Hakonarson   +5 more
wiley   +1 more source

Association of HPA Antigens with Immune Thrombocytopenia: A Case-Control Study by PCR-SSP Method. [PDF]

Int J Hematol Oncol Stem Cell Res
Asgari Nejad S, Hashemzadeh P, Abdolkarimi B, Karimi Rouzbahani A, Anani Sarab G, Varzi AM.   +5 more
europepmc   +1 more source

Diverse potential of chimeric antigen receptor‐engineered cell therapy: Beyond cancer

Clinical and Translational Medicine, Volume 15, Issue 4, April 2025.
1. In theory, CAR‐engineering therapy can achieve therapeutic effects by targeting cells expressing specific antigens and thereby eliminating or regulating disease‐related cell subpopulations. 2. Although CAR‐engineering therapy is currently only approved for the treatment of cancer, it has also shown potential in non‐tumour diseases. 3.
Lvying Wu, Lingfeng Zhu, Jin Chen
wiley   +1 more source

Characterization of Platelet Receptors and Their Involvement in Immune Activation of These Cells. [PDF]

Int J Mol Sci
Tokarz-Deptuła B, Baraniecki Ł, Palma J, Stosik M, Deptuła W.   +4 more
europepmc   +1 more source

Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder [PDF]

, 1988
Beate E. Kehrel, Leopold Balleisen, R Kokott, R M Mesters, W. Stenzinger, KJ Clemetson, J. van de Loo   +6 more
openalex   +1 more source

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Recent advances in vascular thiol isomerases: insights into structures, functions in thrombosis and antithrombotic inhibitor development. [PDF]

Thromb J
Jiang L, Yuan C, Flaumenhaft R, Huang M.
europepmc   +1 more source

Interaction of calmodulin with the cytoplasmic domain of the platelet membrane glycoprotein Ib-IX-V complex

, 2001
Robert K. Andrews, Adam D. Munday, Christina A. Mitchell, Michael C. Berndt   +3 more
openalex   +1 more source